Lonza to Expand Cytotoxic API Capacity in Switzerland

06:48 AM | May 12, 2011 | Deepti Ramesh

Lonza says it will invest SF24 million ($27 million) to expand cytotoxic manufacturing capabilities at the company’s site at Visp, Switzerland. Cytotoxic active pharmaceutical ingredients (APIs) are...